SOD/KKA/mdm-January 21, 2005

AND THE UNITED STATES PATENT AND TRADEMARK OFFICE

(2)	James A. Shayman		adt offici
Application No.:	10/824,708	Group Art Unit:	1621
Filed:	April 15, 2004	Examiner:	Not yet assigned

Confirmation No.: 7244

Title: AMINO CERAMIDE-LIKE COMPOUNDS AND THERAPEUTIC METHODS OF USE

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States
Postal Service with sufficient postage as First Class Mail in an envelope addressed
to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is
being facsimile transmitted to the United States Patent and Trademark Office on:

Signature

Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

		,
Si	r:	
Tl [nis In]	iformation Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[]	X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
[]	under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or [] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
]]	under 37 CFR 1.97(d) together with: [] a Statement under 37 CFR 1.97(e), as checked below, and [] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
[]	under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

Staten	nent Un	der 37 (CFR 1.97(e)
[]	any co	mmuni	information contained in this Information Disclosure Statement was first cited in cation from a foreign patent office in a counterpart foreign application not more nths prior to the filing of this Information Disclosure Statement; or
[]	comm knowl in the	unication ledge of information	formation contained in this Information Disclosure Statement was cited in a confrom a foreign patent office in a counterpart foreign application, and, to the the undersigned, after making reasonable inquiry, no item of information contained ation disclosure statement was known to any individual designated in 37 CFR than three months prior to the filing of this Information Disclosure Statement.
Staten	nent Un	der 37 (CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000
[]	comm was no	unication of receive	information contained in the Information Disclosure Statement was cited in a on from a foreign patent office in a counterpart application and this communication yed by any individual designated in § 1.56(c) more than thirty days prior to the information Disclosure Statement.
[X]	Enclo	sed here	ewith is form PTO-1449:
	[X]	A cop	y of the cited reference is enclosed.
		[]	Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
	[]	Copies Applic applic	s of the cited references are enclosed except those entered in prior application, U.S. cation No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier ation contains copies of the cited references.]
	[]	The lis	sted references were cited in the enclosed International Search Report in a expart foreign application.
	[]	The "cunder	concise explanation" requirement (non-English references) for reference(s) [37 CFR 1.98(a)(3) is satisfied by:
		[]	the explanation provided on the attached sheet.
		[]	the explanation provided in the Specification.
		[]	submission of the enclosed International Search Report.
		[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
		[]	the enclosed English language abstract.

[]	Applic	cant requests that the following r	on-published pending appli	cations be considered:
Examiner Initials	s			
	_	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
	-	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
	_	U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
		Examiner	Date	_
	[]	A copy of each above-cited app any application filed on or after Image File Wrapper (IFW) syst	: June 30, 2003, which has t	peen scanned into the PTO's
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.		ent claims, is enclosed, except], to which priority under
		r is requested to return a copy of re considered with the next offic		plications indicating which
It is re	equested	that the information disclosed h	erein be made of record in t	his application.
Metho	od of pay	vment:		
[]	A chec	ck for the fee noted above is enclopanying Reply. A copy of this S		cluded in the check with the
[]	Please enclos	charge Deposit Account 08-038 ed.	0 in the amount of \$[]. A copy of this Statement is
[X]	Please	charge any deficiency in fees an	d credit any overpayment to	Deposit Account 08-0380.
		F	Respectfully submitted,	
		ŀ	IAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.
		E	Kralg K. Anderson Registration No.: 54,961 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	5

Concord, MA 01742-9133 Dated: June 31, 2005

Sheet I of I

				51.001 1 01
PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3646.1001-013		LICATION NO. 1824,708	
IN AN APPLICATION	FIRST NAMED INVENTOR James A. Shayman	•	FILING DATE April 15, 20	004
January 31, 2005 (Use several sheets if necessary)	Not yet assigned	CONFI 7244	RMATION NO.	GROUP 1621
MOSON				

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AS3	CAPLUS listing of Accession No. 1985:221199, Keith McCullagh et al., "Carboxylalkyl Peptide Derivatives."